AUTOLOGOUS
TISSUE ENGINEERING
Transformative Regenerative Platform
Our proprietary technology creates fully autologous engineered tissues using patient-derived extracellular matrix and iPSCs, enabling personalized, curative therapies with reduced rejection risk.
REGENERATION
WITHOUT REJECTION
WITHOUT REJECTION
PERSONALIZED
HYDROGEL
HYDROGEL
Patient's blood is collected to produce induced Pluripotent Stem Cells (iPSCs)
Small sample of patient's omentum
undergoes a proprietary
decellularization process to form a thermo-responsive hydrogel
undergoes a proprietary
decellularization process to form a thermo-responsive hydrogel
The stem cells are differentiated within the hydrogel to generate the desired tissue
The autologous engineered tissue is implanted to the patient
Novel technology addressing multiple indications
Matricelf’s novel regenerative medicine platform enables treatment of a range of medical conditions including Stroke, TBI (Traumatic Brain Injury), Myocardial Infarction, etc.